Shaanxi Bailu Pharmaceutical

Shaanxi Bailu Pharmaceutical is a Chinese pharmaceutical company specializing in the development, manufacturing, and marketing of Traditional Chinese Medicine (TCM) and chemical drugs. Established in 1978 and headquartered in Xi'an, the company operates two major production bases in Sanyuan County, Shaanxi, producing a wide range of dosage forms including granules, tablets, capsules, and oral liquids. Its flagship product, Rupi Sanjie granules, is a market leader in China for the treatment of breast hyperplasia. The company's portfolio also includes chemical medications for cardiovascular conditions, such as Valsartan and Hydrochlorothiazide tablets, and various TCM formulations for respiratory and inflammatory diseases. Shaanxi Bailu is recognized as a high-tech enterprise and maintains a significant presence in the domestic Chinese healthcare market through its extensive sales network.